



PREDICT AND PROTECT FAST

Strong protection, less vulnerable flocks


Infectious bursal disease virus (IBDV) remains a leading challenge for the commercial egg industry, with many flock health managers relying on recombinant vector vaccines with a herpesvirus of turkeys (HVT) backbone for protection. In 2019, **60% of the U.S.**layer population was vaccinated with a vector HVT-IBD vaccine.²

Every day counts when it comes to IBDV

Timing is everything in egg production. Poulvac® Procerta™ HVT-IBD protects chicks faster and delivers better overall protection to common IBDV challenges, leaving flocks less vulnerable and providing lasting protection.¹

- In a study with no maternal antibodies present, Poulvac
 Procerta HVT-IBD provided 98% protection against a Day 14
 classic IBDV challenge, based on acute bursal lesions.¹
- In a study assessing bursal atrophy in pullets, Poulvac Procerta HVT-IBD provided 100% protection following a Day 14 classic IBDV challenge.³
- Poulvac Procerta HVT-IBD also has demonstrated 90% efficacy at Day 14 against a very virulent IBDV challenge (California isolate) using subcutaneous injection.⁴

Fast protection against critical layer IBDV challenges on Day 14





Strong portfolio offers more customizable solutions

A comprehensive approach addresses the prominent threat. As threats change over time, a robust vaccine portfolio helps ensure you have the right tools to customize your approach and optimize health outcomes.

Low maternal antibodies: Bursine®-2 is a conventional vaccine option when an HVT-LT vaccine is utilized or following subcutaneous application of Poulvac® Procerta™ HVT-IBD.

Marek's disease protection: Poulvac Procerta HVT-IBD is approved for co-administration with Poulvac® Ovoline CVI, which contains low-passage efficacious Rispens CVI-988 strain.

Diagnostics: Zoetis offers an array of services to identify IBDV strains and the timing and severity of challenges.

Layer schools: Zoetis helps train your vaccination crews on proper handling and administration of frozen HVT-IBD vaccines.

"IBDV is one of the leading disease challenges in the commercial egg industry."

— JOHN BROWN, DVM
SENIOR TECHNICAL SERVICES VETERINARIAN, ZOETIS

Service sets us apart

As team players, Zoetis veterinarians and account managers work with customers to achieve their goals. Our knowledgeable team is eager to share IBDV expertise and provide comprehensive production administration training and diagnostic monitoring to ensure customers are successful.

Visit Doulyas Droserta som or talk with your 70 tis representative for more information
Visit PoulvacProcerta.com or talk with your Zoetis representative for more information.
¹ Data on file, Study Report No. B815R-US-19-B20, Zoetis Inc. ² Rennier Associates Inc. 2018 US Broiler-Health Market Tracker. ³ Data on file, Study Report No. B812W-US-18-919, Zoetis Inc.

